NOVEL THERAPIES & NEXT-GEN MEDICAL DEVICES IN CARDIOVASCULAR & VASCULAR DISEASE MANAGEMENT
With
Professor Shirley Jansen AM
The Lawrence-Brown Chair of Vascular Surgery,
School of Population Health,
Curtin University &
Head of the Department of Vascular and Endovascular Surgery,
Sir Charles Gairdner Hospital &
Director of the Heart and Vascular Research Institute,
Harry Perkins Institute of Medical Research, Western Australia
RESEARCHER PROFILE
Filmed in Perth, Australia | June 2026
Professor Shirley Jansen AM is a distinguished vascular and endovascular surgeon whose career spans clinical leadership, academic excellence, and pioneering research. She currently holds the Lawrence-Brown Chair of Vascular Surgery at Curtin University’s School of Population Health and serves as Head of the Department of Vascular Surgery at Sir Charles Gairdner Hospital, a role she has held since 2015. In addition, she is the Director of the Heart & Vascular Research Institute at the Harry Perkins Institute for Medical Research. Her early career was marked by prestigious fellowships, including a British Heart Foundation Research Fellowship (1996), and multiple international travelling fellowships from leading surgical societies and industry sponsors between 2001 and 2002.
Professor Jansen has over 20 years of experience treating vascular disease and has played a vital role in shaping healthcare policy, and clinical standards. She has been Site PI in over 50 clinical trials in pharma, device, first in man, RCTS and registries, many global and leading to changes in practice. She has over 150 peer-reviewed publications, including chapters in key surgical textbooks. Her research has attracted over $14 million in funding, supporting groundbreaking work in biologic therapeutics, vascular medicine, and international clinical trials.
Professor Jansen is Co-Founder and Director of Atherid Therapeutics Pty Ltd developing a novel first in class therapeutic to remove cholesterol and lipid from the arterial wall in atherosclerosis with inventor A/Prof Juliana Hamzah, Head of Targeted Drug Delivery, Imaging and Therapeutics Lab, Harry Perkins Institute of Medical Research. S Jansen’s other main research interest is in the mechanical impacts on the vessel wall as it relates to arterial disease and intervention, and the development of 3D bioprinted vascular devices with her colleague A/Prof Elena Juan Pardo, an expert in bioengineering at the Perkins.
Source: Supplied
-
Patient reported outcomes in the diagnosis and treatment of lymphoma
Dr. Elizabeth Goodall (BMedSci Hons, MBBS Hons, FRACP, FRCPA) is a PhD student and early career researcher with La Trobe University and the Olivia Newton John Cancer Research Institute (ONJCRI), and Haematologist at Austin Health and Monash Health, Melbourne.
Her specific interest in how patients experience their illness and treatment forms the basis for her research in improving patient outcomes. This research comes at a pivotal time in modern lymphoma management with an ever-increasing number of treatment options available and renewed focus on each patient’s journey.
-
Professor Maria Makrides
SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE (SAHMRI)
SOUTH AUSTRALIA
AUSTRALIA
NEW SOUTH WALES, AUSTRALIA -
Systems genetics to determine risk of developing diabetes complications
Dr Mara Zeissig is a recently appointed Lab Head within the Tumour Inflammation and Immunotherapy Program at the South Australian immunoGENomics Cancer Institute (SAiGENCI).
Her research focuses on studying immune evasion mechanisms in lung and pancreatic cancers to identify novel ways to increase response to immunotherapy. Her expertise is in genetically engineered mouse models of lung cancer, CRISPR-Cas9 screening technologies and T cell based immunotherapies (e.g Checkpoint inhibitors).
